Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStatins for the primary prevention of cardiovascular diseaseStatins for the primary prevention of cardiovascular diseaseHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisEfficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysisThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBlood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analysesMonitoring kidney function and albuminuria in patients with diabetes.Vascular calcification: When should we interfere in chronic kidney disease patients and how?Statins in the treatment of chronic heart failure: a systematic reviewEffect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trialsReducing the costs of chronic kidney disease while delivering quality health care: a call to action.Primary prevention of CVD: treating dyslipidaemia.Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.Disorders of lipid metabolism and chronic kidney disease in the elderlyAssociation between kidney function and albuminuria with cardiovascular events in HIV-infected personsPrevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients.World kidney day 2011: protect your kidneys, save your heart.Predictors of urinary albumin excretion in women with polycystic ovary syndromePhysical activity is inversely associated with microalbuminuria in hypertensive patients at high cardiovascular risk: data from I-SEARCH.Predicting hospital cost in CKD patients through blood chemistry valuesPredicting the outcome of chronic kidney disease by the estimated nephron number: the rationale and design of PRONEP, a prospective, multicenter, observational cohort study.Renal protection in diabetes: lessons from ONTARGET.Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease.Safety of ACE inhibitor therapies in patients with chronic kidney disease.Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?Association of renal biomarkers with 3-month and 1-year outcomes among critically ill acute stroke patients.A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study.Chronic kidney disease: a public health problem that needs a public health action planHigh-normal albuminuria and risk of heart failure in the community.Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registPredictors of incident albuminuria in the Framingham Offspring cohort.Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.World Kidney Day 2011 - Protect your kidneys, save your heart.Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.Emerging drug combinations to optimize renovascular protection and blood pressure goals.The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.Urinary albumin-creatinine ratio, estimated glomerular filtration rate, and all-cause mortality among US adults with obstructive lung function.Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients
P2860
Q24194514-0E4E6ECE-1291-4FB2-9954-FC4B15547F60Q24201513-E7484FD4-2EDF-4C98-B512-CC625AA85E9DQ24234813-C1FBB646-16C3-4CAC-A641-3F8483E5E475Q24241472-A86CB362-0C33-43DC-9B7F-E14644A64B98Q24628361-091BCE59-E376-4056-8F30-72EF1B748A5DQ24646234-04745DC4-F7C9-4B85-8F71-3E2E0B1E9D25Q26996563-CDA09093-5B5A-4A53-8DF0-5D5B819959BEQ27691297-2D9A2975-43AA-4EF6-8AD0-9A0B1BC42C97Q28071582-E22785AC-8C70-4221-9E5A-066C25B918E2Q28200294-BDA146D1-F5DE-48A7-BD3D-7469A0DA2542Q28483807-0D30B111-AE62-475C-BD90-4EA3AC3D8D91Q30234324-8D94F602-B438-45E7-BD3F-0F196CA33589Q33446730-984AABA8-C0F7-4FD2-999E-064088E99773Q33588706-41072FB6-917C-4C3E-AE27-0F5CD3377F16Q33589563-4063FDCD-141F-40A6-8E71-26E2B70E64F7Q33692733-AE08F2BA-BE16-4041-8E32-3129A98A6BE4Q33813773-F9426277-5CE8-45BF-875D-B804E40AD03AQ33871733-FB225DB0-D6D5-49C0-8D0D-67464C280AE7Q33889835-179EF580-887F-4E6D-8137-0C104E9CE060Q34013444-6FB03848-B4A2-4B36-A3C0-9B0DE6CB5FC2Q34088691-C33C33BE-867A-4072-BF12-ED4355111D4CQ34190377-916097B3-394E-474B-9599-85553365AE9BQ34221460-198EEE29-112D-462F-A78A-780BDEDB0B32Q34407904-AD16F829-474A-4109-A3E9-FBB4D3861B33Q34434606-EE3854FA-2905-4065-A88B-6E98BFEB3B03Q34613884-BC2DD764-B93F-4BFD-BF7A-DDD9E479FE73Q34980234-99719982-AAC9-418D-B6EE-265953BEC449Q34994258-97B52A48-5A8B-4DCA-9455-238C6B524493Q35023531-FBED763B-C787-4F55-8B15-4CBDE2A0EB25Q35024506-9B12D7DF-70A8-491E-96C1-900D35E83EE6Q35058809-D7B715B8-738C-4D4C-AB3E-5040A48DDFA9Q35224623-0EFE0B14-99B8-4591-BA6A-2CA3E008F8A5Q35404652-339493AF-8E3A-4872-9B9C-54C8964DA983Q35576102-BF02379C-CADE-48CE-A974-FA5077987BB1Q35673984-1BAB266A-D5F8-44CC-976D-77861C124F66Q35856929-84CA0302-92FC-4EC9-A564-8D6C7FE9194DQ35905899-35217E10-4FF5-44FE-BD7E-28DBBD748A67Q36017400-1E03CBEE-7A37-4421-B810-5F3C45902F7CQ36087862-C5940C0D-945C-4FD0-A914-D2E824578E4EQ36285590-EB0914BF-105A-430E-8D8B-E6747976615D
P2860
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@en
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@nl
type
label
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@en
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@nl
prefLabel
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@en
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@nl
P2093
P50
P1433
P1476
Effects of fosinopril and prav ...... ubjects with microalbuminuria.
@en
P2093
Ad J van Boven
Adriaan A Voors
Dick de Zeeuw
Gilles F H Diercks
Hans L Hillege
Paul E de Jong
Prevention of Renal and Vascul ...... ial (PREVEND IT) Investigators
Wilbert M T Janssen
P304
P356
10.1161/01.CIR.0000146378.65439.7A
P407
P577
2004-10-18T00:00:00Z